{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:48:17Z","timestamp":1753876097606,"version":"3.41.2"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>No models predict future outcomes in inflammatory bowel disease (IBD) patients receiving maintenance infliximab therapy. We created a predictive model for unfavorable outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Adult patients with IBD receiving maintenance infliximab therapy at 2 centers with matched serum infliximab concentrations and blinded histologic scores (Robarts Histopathologic Index [RHI]) were included. The primary endpoint was an unfavorable outcome of active objective inflammation or need for IBD-related surgery or hospitalization at 6\u201318 months follow-up. Internal variables were identified using univariable analyses, modeling used multivariable analysis, and performance was assessed (area under receiver-operating curve [AUC]) and externally validated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In 81 patients, 40.7% developed unfavorable outcomes at follow-up. Infliximab concentration &amp;lt;9.3 \u00b5g\/mL (odds ratio [OR] 5.3, P\u2005=\u2005.001) and RHI\u2005&amp;gt;\u200512 (OR 3.4, P\u2005=\u2005.03) were the only factors associated with developing the primary unfavorable outcome. A prediction score assigning 1 point to each variable had good discrimination and performed similarly on internal (AUC 0.71) and external (AUC 0.73) cohorts. The risk of primary unfavorable outcomes in internal and external cohorts, respectively, was 23% and 15% for a score of 0, 46% and 50% for a score of 1, and 100% and 75% for a score of 2. Infliximab concentration alone performed similar to the 2-predictor model in internal (AUC 0.65, P\u2005=\u2005.5 vs. 2-predictor model) and external (AUC 0.70, P\u2005=\u2005.9, vs. 2-predictor model) cohorts.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Using unbiased variable selection, a 2-predictor model using infliximab concentrations and histology identified IBD patients on maintenance infliximab therapy at high risk of future unfavorable outcomes. For practical applicability, infliximab concentrations alone performed similarly well.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/crocol\/otae052","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T10:33:04Z","timestamp":1732271584000},"source":"Crossref","is-referenced-by-count":0,"title":["Predictive Model for Outcomes in Inflammatory Bowel Disease Patients Receiving Maintenance Infliximab Therapy"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3326-3360","authenticated-orcid":false,"given":"Rochelle","family":"Wong","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Liver Diseases, Department of Medicine, University of Southern California , Los Angeles, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5512-4225","authenticated-orcid":false,"given":"Paris","family":"Charilaou","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Gastroenterology and Hepatology, Wake Forest Medical School , Charlotte, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Hemperly","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, University of California, San Diego , La Jolla, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihui","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Pathology, Weill Cornell Medicine , New York, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushan","family":"Pan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine , New York, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prerna","family":"Mathani","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine , New York, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randy","family":"Longman","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine , New York, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigid S","family":"Boland","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, University of California, San Diego , La Jolla, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parambir S","family":"Dulai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Northwestern University , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariela K","family":"Holmer","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, NYU Langone Health , New York, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Lukin","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine , New York, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddharth","family":"Singh","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, University of California, San Diego , La Jolla, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A","family":"Valasek","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of California, San Diego , La Jolla, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J","family":"Sandborn","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, University of California, San Diego , La Jolla, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Scherl","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine , New York, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0854-0274","authenticated-orcid":false,"given":"Niels","family":"Vande Casteele","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, University of California, San Diego , La Jolla, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7421-9764","authenticated-orcid":false,"given":"Robert","family":"Battat","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University of Montreal , Montreal, Quebec ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,11,22]]},"reference":[{"issue":"9317","key":"2024121406565672300_CIT0001","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease:","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet."},{"issue":"9","key":"2024121406565672300_CIT0002","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol."},{"issue":"12","key":"2024121406565672300_CIT0003","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1038\/ajg.2016.418","article-title":"Histological disease activity as a predictor of clinical relapse among patients with ulcerative colitis: systematic review and meta-analysis","volume":"111","author":"Park","year":"2016","journal-title":"Am J Gastroenterol."},{"issue":"9","key":"2024121406565672300_CIT0004","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1002\/ibd.21925","article-title":"Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation","volume":"18","author":"Baars","year":"2012","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2024121406565672300_CIT0005","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5217\/ir.2018.16.1.55","article-title":"Association of endoscopic and histological remission with clinical course in patients of ulcerative colitis","volume":"16","author":"Narang","year":"2018","journal-title":"Intest Res"},{"issue":"3","key":"2024121406565672300_CIT0006","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1136\/gutjnl-2015-309598","article-title":"Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up","volume":"65","author":"Bryant","year":"2016","journal-title":"Gut."},{"issue":"5","key":"2024121406565672300_CIT0007","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/ajg.2016.50","article-title":"Histology grade is independently associated with relapse risk in patients with ulcerative colitis in clinical remission: a prospective study","volume":"111","author":"Zenlea","year":"2016","journal-title":"Am J Gastroenterol."},{"issue":"9","key":"2024121406565672300_CIT0008","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.cgh.2020.09.046","article-title":"Treat to target: the role of histologic healing in inflammatory bowel diseases: a systematic review and meta-analysis","volume":"19","author":"Gupta","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"2024121406565672300_CIT0009","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1136\/gutjnl-2015-310393","article-title":"Development and validation of a histological index for UC","volume":"66","author":"Mosli","year":"2017","journal-title":"Gut."},{"issue":"4","key":"2024121406565672300_CIT0010","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3390\/jcm11040939","article-title":"Histological scores in patients with inflammatory bowel diseases: the state of the art","volume":"11","author":"Vespa","year":"2022","journal-title":"J Clin Med"},{"issue":"6","key":"2024121406565672300_CIT0011","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.gie.2018.08.018","article-title":"The emerging role of histologic disease activity assessment in ulcerative colitis","volume":"88","author":"Pai","year":"2018","journal-title":"Gastrointest Endosc."},{"issue":"7","key":"2024121406565672300_CIT0012","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/apt.16248","article-title":"An expert consensus to standardise the assessment of histological disease activity in Crohn\u2019s disease clinical trials","volume":"53","author":"Almradi","year":"2021","journal-title":"Aliment Pharmacol Ther."},{"issue":"4","key":"2024121406565672300_CIT0013","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1053\/j.gastro.2021.06.015","article-title":"Histologic outcomes with vedolizumab versus adalimumab in ulcerative colitis: results from an efficacy and safety study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY)","volume":"161","author":"Peyrin-Biroulet","year":"2021","journal-title":"Gastroenterology."},{"issue":"4","key":"2024121406565672300_CIT0014","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1053\/j.gastro.2019.05.067","article-title":"Vedolizumab induces endoscopic and histologic remission in patients with Crohn\u2019s disease","volume":"157","author":"L\u00f6wenberg","year":"2019","journal-title":"Gastroenterology."},{"issue":"7","key":"2024121406565672300_CIT0015","doi-asserted-by":"publisher","first-page":"CD012351","DOI":"10.1002\/14651858.CD012351.pub2","article-title":"Histologic scoring indices for evaluation of disease activity in Crohn\u2019s disease","volume":"2017","author":"Novak","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"issue":"9","key":"2024121406565672300_CIT0016","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1016\/j.cgh.2023.11.032","article-title":"Reliability and responsiveness of histologic indices for the assessment of Crohn\u2019s disease activity","volume":"22","author":"Solitano","year":"2023","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"3","key":"2024121406565672300_CIT0017","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/jgh3.12260","article-title":"Relationship between mayo endoscopic score and histological scores in ulcerative colitis: a prospective study","volume":"4","author":"Shah","year":"2019","journal-title":"JGH Open"},{"key":"2024121406565672300_CIT0018","doi-asserted-by":"publisher","first-page":"i103","DOI":"10.1093\/ecco-jcc\/jjab232.095","article-title":"DOP56 Histologic disease activity correlates with endoscopic severity in patients with moderate to severe Crohn\u2019s disease","volume":"16","author":"Reinisch","year":"2022","journal-title":"J Crohns Colitis."},{"issue":"9","key":"2024121406565672300_CIT0019","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/j.cgh.2023.11.010","article-title":"Effects of mirikizumab on histologic resolution of Crohn\u2019s disease in a randomized controlled phase 2 trial","volume":"22","author":"Magro","year":"2024","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"5","key":"2024121406565672300_CIT0020","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/ajg.2010.9","article-title":"Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease","volume":"105","author":"Afif","year":"2010","journal-title":"Am J Gastroenterol."},{"issue":"6","key":"2024121406565672300_CIT0021","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1053\/j.gastro.2014.08.035","article-title":"Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis","volume":"147","author":"Adedokun","year":"2014","journal-title":"Gastroenterology."},{"issue":"4","key":"2024121406565672300_CIT0022","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.cgh.2015.10.025","article-title":"Optimizing Anti-TNF-\u03b1 therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases","volume":"14","author":"Ungar","year":"2016","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"5","key":"2024121406565672300_CIT0023","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/ecco-jcc\/jjw007","article-title":"Systematic review and meta-analysis: serum infliximab levels during maintenance therapy and outcomes in inflammatory bowel disease","volume":"10","author":"Moore","year":"2016","journal-title":"J Crohns Colitis."},{"issue":"1","key":"2024121406565672300_CIT0024","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1365-2036.2006.03131.x","article-title":"Systematic review: infliximab therapy in ulcerative colitis","volume":"25","author":"Gisbert","year":"2007","journal-title":"Aliment Pharmacol Ther."},{"issue":"2","key":"2024121406565672300_CIT0025","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/ibd\/izab042","article-title":"Collecting new peak and intermediate infliximab levels to predict remission in inflammatory bowel diseases","volume":"28","author":"Liefferinckx","year":"2022","journal-title":"Inflamm Bowel Dis."},{"issue":"3","key":"2024121406565672300_CIT0026","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology."},{"issue":"10","key":"2024121406565672300_CIT0027","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.3390\/jcm12103378","article-title":"Therapeutic drug monitoring of infliximab in acute severe ulcerative colitis","volume":"12","author":"Gordon","year":"2023","journal-title":"J Clin Med"},{"issue":"12","key":"2024121406565672300_CIT0028","first-page":"656","article-title":"Etiology and management of lack or loss of response to anti\u2013tumor necrosis factor therapy in patients with inflammatory bowel disease","volume":"15","author":"Fine","year":"2019","journal-title":"Gastroenterol Hepatol"},{"issue":"5","key":"2024121406565672300_CIT0029","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/j.1524-4733.2008.00335.x","article-title":"Loss of treatment response to infliximab maintenance therapy in Crohn\u2019s disease: a payor perspective","volume":"11","author":"Wu","year":"2008","journal-title":"Value Health."},{"issue":"3","key":"2024121406565672300_CIT0030","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.cgh.2020.03.072","article-title":"Baseline clearance of infliximab is associated with requirement for colectomy in patients with acute severe ulcerative colitis","volume":"19","author":"Battat","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"7","key":"2024121406565672300_CIT0031","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.clinthera.2011.06.002","article-title":"Pharmacokinetic properties of infliximab in children and adults with Crohn\u2019s disease: a retrospective analysis of data from 2 phase III clinical trials","volume":"33","author":"Fasanmade","year":"2011","journal-title":"Clin Ther."},{"issue":"4","key":"2024121406565672300_CIT0032","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1053\/j.gastro.2019.06.038","article-title":"Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn\u2019s disease","volume":"157","author":"Danese","year":"2019","journal-title":"Gastroenterology."},{"issue":"1","key":"2024121406565672300_CIT0033","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1053\/j.gastro.2011.09.034","article-title":"Maintenance of remission among patients with Crohn\u2019s disease on antimetabolite therapy after infliximab therapy is stopped","volume":"142","author":"Louis","year":"2012","journal-title":"Gastroenterology."},{"issue":"9","key":"2024121406565672300_CIT0034","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nmeth.3968","article-title":"Points of significance: model selection and overfitting","volume":"13","author":"Lever","year":"2016","journal-title":"Nat Methods."},{"issue":"1","key":"2024121406565672300_CIT0035","doi-asserted-by":"publisher","first-page":"55","DOI":"10.7326\/M14-0697","article-title":"Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement","volume":"162","author":"Collins","year":"2015","journal-title":"Ann Intern Med."},{"issue":"5","key":"2024121406565672300_CIT0036","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn\u2019s disease (PROFILE): a multicentre, open-label randomised controlled trial","volume":"9","author":"Noor","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"5","key":"2024121406565672300_CIT0037","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"issue":"10","key":"2024121406565672300_CIT0038","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1111\/apt.16083","article-title":"Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study","volume":"52","author":"Battat","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"2024121406565672300_CIT0039","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/gutjnl-2015-310187","article-title":"Development and validation of the Nancy Histological Index for UC","volume":"66","author":"Marchal-Bressenot","year":"2017","journal-title":"Gut."},{"issue":"4","key":"2024121406565672300_CIT0040","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/apt.14458","article-title":"Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis","volume":"47","author":"Papamichael","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"2024121406565672300_CIT0041","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1093\/ibd\/izy132","article-title":"Association between serum infliximab trough concentrations during maintenance therapy and biochemical, endoscopic, and histologic remission in Crohn\u2019s disease","volume":"24","author":"Papamichael","year":"2018","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2024121406565672300_CIT0042","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12876-021-01650-7","article-title":"High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study","volume":"21","author":"Wilson","year":"2021","journal-title":"BMC Gastroenterol."},{"issue":"3","key":"2024121406565672300_CIT0043","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4103\/1319-3767.80383","article-title":"Biological and histological parameters as predictors of relapse in ulcerative colitis: a prospective study","volume":"17","author":"Azad","year":"2011","journal-title":"Saudi J Gastroenterol"},{"issue":"11","key":"2024121406565672300_CIT0044","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/ajg.2012.301","article-title":"Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing","volume":"107","author":"Bessissow","year":"2012","journal-title":"Am J Gastroenterol."},{"issue":"5","key":"2024121406565672300_CIT0045","doi-asserted-by":"publisher","first-page":"733","DOI":"10.14309\/ajg.0000000000000111","article-title":"Histologic healing rates of medical therapies for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials","volume":"114","author":"Battat","year":"2019","journal-title":"Am J Gastroenterol."},{"issue":"5","key":"2024121406565672300_CIT0046","doi-asserted-by":"publisher","first-page":"CD011256","DOI":"10.1002\/14651858.CD011256.pub2","article-title":"Histologic scoring indices for evaluation of disease activity in ulcerative colitis","volume":"2017","author":"Mosli","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"issue":"5","key":"2024121406565672300_CIT0047","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1007\/s10620-018-4980-0","article-title":"Fecal calprotectin in assessing endoscopic and histological remission in patients with ulcerative colitis","volume":"63","author":"Mak","year":"2018","journal-title":"Dig Dis Sci."}],"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otae052\/60785650\/otae052.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/6\/4\/otae052\/60937625\/otae052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/6\/4\/otae052\/60937625\/otae052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T06:57:07Z","timestamp":1734159427000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otae052\/7906862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otae052","relation":{},"ISSN":["2631-827X"],"issn-type":[{"type":"electronic","value":"2631-827X"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,10,1]]},"article-number":"otae052"}}